Source: Health Affairs, 2013
Authors: Steve Morgan, Jamie Daw, Paige Thomson
Reimbursement contracts, in which health insurers receive rebates from drug manufacturers instead of paying the transparent list price, are becoming increasingly common worldwide. Through interviews... Read more
Source: Canadian Journal of Emergency Medicine, 2013
Authors: Barbara J. Hill-Taylor, Katrina F. Hurley, Ingrid Sketris, Colleen O'Connell, Douglas Sinclair, Andrew Wing
ObjectiveThe primary objective of this study was to quantify the impact of a clinical practice intervention to promote the delivery of salbutamol by metered-dose inhaler (MDI) in a pediatric... Read more
Source: BMC Health Services Research, 2013
Authors: Danielle Bishop, Joel Lexchin
BackgroundPressures on health care budgets have led policy makers to discuss how to balance the provision of costly technologies to populations in need and making coverage decisions under uncertainty... Read more
Source: Journal of Health Politics, Policy and Law, 2013
Authors: Joel Lexchin, Mary Wiktorowicz, Kathy Moscou, Laura Eggertson
The Canadian constitution divides the responsibility for pharmaceuticals between the federal and provincial governments. While the provincial governments are responsible for establishing public... Read more
Source: Open Medicine, 2010
Authors: Joel Lexchin
The Patented Medicine Prices Review Board (PMPRB) regulates the introductory price of new patented medications in Canada. Some drugs are marketed before they are patented and are therefore outside... Read more
Source: BMJ, 2008
Authors: Michael R. Law, Sumit R. Majumdar, Stephen B. Soumerai
Purpose of StudyThe purpose of this study was to assess the impact of US DTCA on Canadian prescribing rates for three heavily marketed drugsóetanercept, mometasone, and tegaserod. Research Approach/... Read more
Steve Morgan
Ingrid S. Sketris
Joel Lexchin
Michael Law